BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation® (NYSE: TGX - News), a medical device company serving the prostate cancer treatment and surgical products markets, today announced consolidated financial results for the third quarter and nine months ended September 30, 2007. Consolidated revenue for the quarter was $16.0 million compared to $14.3 million in the third quarter of 2006, an increase of 12%. For the nine-month period, consolidated revenue was $47.0 million, compared to $39.3 million in the 2006 period, an increase of 20%. Net income for the quarter was $1.8 million, or $0.05 per share on a diluted basis, compared to net income of $1.7 million, or $0.05 per share on a diluted basis in the third quarter of 2006. For the nine-month period, net income was $4.5 million, or $0.13 per share on a diluted basis, compared to net income of $2.9 million, or $0.09 per share on a diluted basis in 2006. Results for the 2006 periods include the results of Galt Medical from August 2, 2006, the date Galt was acquired by Theragenics.
